# Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

> **NCT00624585** · NA · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 18 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00624585
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00624585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00624585, "Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00624585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*